Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05131646 · ClinicalTrials.gov registry record
Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study
A clinical trial of Neovascular Age-related Macular Degeneration, sponsored by Clearside Biomedical.
- Completed
- Registry status
- 15
- Enrollment target
- 7
- Study locations
NCT05131646: Completed study of Neovascular Age-related Macular Degeneration, sponsored by Clearside Biomedical.
NCT05131646 is a study of Neovascular Age-related Macular Degeneration that has completed, run by Clearside Biomedical. The registered enrollment target is 15 participants, below the 408-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (96% lower). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05131646, a study of Neovascular Age-related Macular Degeneration, has completed, sponsored by Clearside Biomedical.
- COMPLETED
- Registry status
- 15 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is an open-label, non-interventional extension study of up to 12 weeks in duration in subjects completing Cohorts 2, 3, and 4 of the Parent study, CLS1002-101.
Primary Outcome
The number of participants with treatment-emergent adverse events (TEAEs) reported between the administration of CLS-AX and study exit.
Conditions Studied
Interventions
- DRUG CLS-AX
Study Locations (7)
California
- Northern California Retina Vitreous Associates Medical Group, LLC - Mountain View
- Retina Consultants Medical Group, Inc - Sacramento
Texas
- Retina Consultants of Texas - Bellaire
- Retina Consultants of Texas - The Woodlands
Arizona
- Retinal Consultants of Arizona - Phoenix
Georgia
- Southeast Retina Center - Augusta
Maryland
- Cumberland Valley Retina Consultants - Hagerstown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-10-08 |
| Est. Completion | 2023-01-05 |
What the finished NCT05131646 record still lists
NCT05131646 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 408-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Neovascular Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which CLS-AX is the first listed.
NCT05131646 lists 7 locations in 5 states (California, Texas, Arizona).
Frequently Asked Questions
What is clinical trial NCT05131646 about?
NCT05131646 is a clinical study titled "Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study". This is an open-label, non-interventional extension study of up to 12 weeks in duration in subjects completing Cohorts 2, 3, and 4 of the Parent study, CLS1002-101.
What is the current status of trial NCT05131646?
This trial is currently completed. The enrollment target is 15 participants. The study started on 2021-10-08. Estimated completion is 2023-01-05.
What conditions does trial NCT05131646 study?
This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration.
What interventions are being tested in trial NCT05131646?
The interventions under investigation include: CLS-AX (DRUG).
Who is sponsoring clinical trial NCT05131646?
This trial is sponsored by Clearside Biomedical, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05131646 being conducted?
This trial has 7 study locations across Arizona, California, Georgia, Maryland, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05131646's enrollment target sits among peer trials
15 33rd of 33 the lowest of 33 other Neovascular Age-related Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neovascular Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
RECRUITING · Phase 1
-
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
RECRUITING · Phase 3
-
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
RECRUITING · Phase 1
-
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
RECRUITING · Phase 3
-
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
RECRUITING · Phase 2
-
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI